Efficacy highlights: - 85% vs severe disease after 28d (often mild hypoxia as case definition) -100% against severe disease requiring hospitalization Again, a two dose regimen trial is underway to see if we can increase numbers further.
-
-
Show this thread
-
Transmission prevention
Protection against asymptomatic infection = 74% efficacy
(seroconversion without prior symptoms, subgroup analysis)
Very promising for transmission prevention.
A one dose vaccine with limited cold chain reliance is a likely game changer for the USpic.twitter.com/o1nKFSbbVw
Show this thread
End of conversation
New conversation -
-
-
Let's get this on air...
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
I am so excited!!!! I hope this will let my siblings and young adult children be vaccinated sooner. Most of the people I love are 20-55 yo and generally healthy. But having worked in the COVID ICU, I know they are still at risk of severe lingering illness or even death.
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
This is great news for the world. Thank you so much for your hard work.
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
what are the adverse side effects? there seem to be many with the other two vaccines
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
Can you explain why this vaccine prevents transmission 74% please? Like dumb it down for me a bit so I can explain it to others.
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
Congratulations! This is great news for the world.
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.
I fight infectious diseases. Opinions are solely my own & do not express the views of my employer or the US Government.